A randomised, double-blind, placebo-controlled, multi-national, multi-centre, Phase III paediatric study of the efficacy and safety of one dose of sublingual immunotherapy (SLIT) administered as allergen-based tablets once daily to children suffering from grass pollen rhinoconjunctivitis

Trial Profile

A randomised, double-blind, placebo-controlled, multi-national, multi-centre, Phase III paediatric study of the efficacy and safety of one dose of sublingual immunotherapy (SLIT) administered as allergen-based tablets once daily to children suffering from grass pollen rhinoconjunctivitis

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Nov 2012

At a glance

  • Drugs Grass pollen allergy immunotherapy (Primary)
  • Indications Allergic rhinoconjunctivitis
  • Focus Registrational; Therapeutic Use
  • Sponsors Stallergenes SA
  • Most Recent Events

    • 26 Nov 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top